The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial-Reference-Cited by-同舟云学术

The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial

Published:2021-11 Issue:12 Volume:73 Page:2206-2218
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Winkler Aaron¹^ORCID,Sun Weiyong¹,De Saurav²,Jiao Aiping¹,Sharif M. Nusrat¹,Symanowicz Peter T.¹,Athale Shruti³,Shin Julia H.¹,Wang Ju¹,Jacobson Bruce A.¹,Ramsey Simeon J.¹,Dower Ken¹,Andreyeva Tatyana¹,Liu Heng¹,Hegen Martin¹,Homer Bruce L.¹,Brodfuehrer Joanne¹,Tilley Mera¹,Gilbert Steven A.¹,Danto Spencer I.¹,Beebe Jean J.¹,Barnes Betsy J.²,Pascual Virginia³,Lin Lih‐Ling¹,Kilty Iain¹,Fleming Margaret¹,Rao Vikram R.¹

Affiliation:

1. Pfizer Cambridge Massachusetts

2. The Feinstein Institute Manhasset New York

3. Baylor Institute for Immunology Research Dallas Texas

Funder

National Institutes of Health

Pfizer

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy